Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2010

View Archived Issues

Correlation between genetic variations in Lp(a) lipoprotein and risk of CAD identified

Crystal structure of PI3Kdelta in complex with inhibitors allows design of enhanced agents

Novo Nordisk: 2009 in review

Rexahn provides update on goals for 2010

Nippon Shinyaku and Actelion enter into license agreement on novel PAH therapeutic

Biodegradable nanocarriers with drug delivery and imaging properties described as theranostic agents

Otonomy receives FDA clearance for trial in Meniere's disease

Pulmonary blood density measured by MRI may be used in PAH and heart failure prognosis

Javelin receives FDA PDUFA date for Dyloject NDA for pain

Ligand reports discovery of dual AT1/ETA receptor antagonists

Roche presents novel CCR2 antagonists

Cardiac reserve index differentiates heart failure patients from healthy subjects

Marcadia Biotech initiates phase I trial of MAR-701

Genfit reports the identification of novel PPAR agonists

Georgetown University discloses MLCP inhibitors for cancer therapy

Merck KGaA discloses novel SphK1 and Met kinase inhibitors

MorphoSys and Galapagos add another antibody target to alliance in bone and joint diseases

TD2 and Rondaxe sign alliance to help emerging companies develop cancer therapeutics

BioMimetic completes submission of PMA to FDA for Augment Bone Graft

Biogen and Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc

Michael J. Fox Foundation funds research into LRRK2 gene

Hollis-Eden Pharmaceuticals becomes Harbor BioSciences

FDA issues complete response letter for GSK's Horizant in RLS

Pharmasset updates progress of RG-7128 studies

Pivotal Research adds U.S. center to phase II study of VA-111913 for dysmenorrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...